Idorsia effectively started its operation after demerging from Actelion on 15 June 2017, and registered shares of Idorsia Ltd were listed on the SIX Swiss Stock Exchange on the next day. As of this date, Idorsia was fully operational with over 600 employees, with a rich clinical development pipeline of ten assets, equipped with state-of-the-art facilities and funded with CHF 1 billion.


Non-GAAP operating loss amounted to CHF 10 mn, driven by Research and Development expenses of CHF 8 mn and G&A expenses of CHF 2 mn. Non-GAAP net loss amounted to CHF 10 mn, Non-GAAP net loss per share amounted to CHF 0.10, based on 106 million of shares outstanding (time-weighted average).

US GAAP operating loss amounted to CHF 11 million, driven by R&D expenses of CHF 8 million, G&A expenses of CHF 2 million. US GAAP net loss amounted to CHF 11 million. US GAAP net loss per share amounted to CHF 0.11, based on 106 million of shares outstanding (time-weighted average).

 

 Idorsia's key numbers

Period ended June 30, 2017

 

 

 

(in CHF millions, except EPS)

US GAAP

Non-GAAP

Operating income (loss)

(11)

(10)

Net income (loss)

(11)

(10)

Basic and diluted EPS

(0.11)

(0.10)

Number of shares (weighted average)

106.023

106.023